Tisagenlecleucel versus historical standard therapies for pediatric relapsed/refractory acute lymphoblastic leukemia.

Conclusion: The analysis demonstrated tisagenlecleucel was associated with substantially greater survival benefit versus all SOC regimens.
PMID: 32602756 [PubMed - as supplied by publisher]

Source: Journal of Comparative Effectiveness Research - July 2, 2020 Category: General Medicine Tags: J Comp Eff Res Source Type: research